|
|
|
|
|
|
|
|
|
|
|
15.10.25 - 22:18
|
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters′ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the closing of its previously announced underwritten public offering of 17,094,594 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 2,229,729 additional shares, at a public offering price per share of $18.50. The gross proceeds to Spyre from the offering were approximately $316.2 million before deducting underwriting discounts and commissions and other offering expenses payable by Spyre....
|
|
|
|
|
14.10.25 - 03:09
|
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 14,864,865 shares of its common stock at a price to the public of $18.50 per share. The gross proceeds to the Company from this offering are expected to be approximately $275.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,229,729 shares of the Company's common stock at the public offering price, less the underwriting discount....
|
|
|
|
|
|
|
|
|
03.10.25 - 22:06
|
Spyre Therapeutics Announces Grants of Inducement Awards (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 42,500 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on October 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
|
06.06.25 - 22:09
|
Spyre Therapeutics Announces Grants of Inducement Awards (PR Newswire)
|
|
|
WALTHAM, Mass., June 6, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and......
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
